查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1840891

非鴉片類止痛貼市場（按技術、應用、產品類型、最終用戶、分銷管道和藥物類型）—2025-2032 年全球預測

Non-opioid Pain Patches Market by Technology, Application, Product Type, End User, Distribution Channel, Drug Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年非鴉片類止痛貼市場規模將成長至 21.4046 億美元，複合年成長率為 13.25%。

主要市場統計數據
基準年2024年 7.9097億美元
預計2025年 8.9706億美元
預測年份：2032年 2,140,​​460,000美元
複合年成長率（%） 13.25%

執行介紹強調了非鴉片類經皮止痛貼生態系統的臨床需求、技術進步和策略要點

非鴉片類止痛貼片領域正隨著醫藥創新、先進材料科學和不斷發展的臨床實踐的交匯而日益成熟。隨著臨床醫生和患者尋求能夠同時緩解急性和慢性疼痛途徑的局部、鴉片類藥物替代療法，新型經皮系統正日益受到青睞。與傳統的外用製劑相比，黏合劑化學、微加工技術和微創給藥機制的同步進步，使得藥物的生物有效性得以提高，療效也更加穩定。

臨床醫師越來越重視那些具有可預測藥物動力學、降低全身暴露量並適應現有治療途徑的產品。同時，製造商正在開發以患者為中心的產品，包括穿戴式性、皮膚耐受性和診所外給藥的便利性。因此，策略決策取決於整合臨床證據、監管透明度和供應鏈韌性。本執行摘要的其餘部分整合了這些因素，重點介紹了關鍵的技術變革、監管和貿易逆風、細分市場主導的商業機會，以及行業領導者可以採用的實用建議，以便將技術前景轉化為商業性和臨床影響。

深入綜合技術、臨床和給藥創新的融合，重塑非鴉片類經皮鎮痛策略和供應商的採用

非鴉片類止痛貼片領域正在經歷一場變革，這得益於給藥技術、黏合劑科學和實證臨床應用的融合發展。微針陣列（包括可溶解和固態形式）正在從學術原型走向可擴展生產，從而能夠經經皮獲取先前受皮膚滲透性限制的分子。同時，包括丙烯酸樹脂、水凝膠和矽酮在內的黏合劑平台也在不斷發展，以平衡藥物相容性和患者舒適度，從而提高急性和慢性護理環境中的依從性。

同時，產品設計在基質、微針和儲庫配置方面呈現差異化，凝膠和液體儲庫配方日益受到關注。這些配方可實現更精確的劑量控制和緩釋性特性，最終減少對全身性止痛藥的需求。隨著醫院、診所和居家照護機構將貼片整合到多種疼痛治療方案中，臨床路徑也不斷調整，不僅關注關節炎和神經病變疼痛等慢性疾病，還關注術後和運動相關的急性疼痛。此外，從依從性感測器到與電子健康記錄的整合，數位化能正在提升監測療效和支持報銷對話的潛力。這些轉變共同創造了一個更加差異化的競爭格局，其中臨床檢驗和生產規模是關鍵促進因素。

基於證據的分析：2025 年美國關稅將如何影響經皮藥物供應鏈的彈性、籌資策略和製造決策

2025年生效的美國關稅措施，對醫療設備供應鏈、原料採購以及支持經皮貼片生產的零件進口造成了顯著的摩擦。影響聚合物、黏合劑前驅物、電子感測器模組和專用微針製造設備的關稅調整，迫使製造商重新評估其供應商關係和生產佈局。為此，一些公司正在優先考慮關鍵投入的近岸外包，尋找替代材料來源，並加速垂直整合，以緩衝成本波動和前置作業時間風險。

關稅不僅影響直接投入成本，還影響商業決策，例如庫存策略和與目標商標產品製造商的合約條款。採購團隊擴大與供應商協商長期契約，以穩定單位成本並遵守生產計劃。監管備案和品管流程也受到影響，因為製造商在供應商變更時檢驗零件。此外，關稅也透過改變資本配置間接影響創新時間表。考慮投資自動化、無塵室擴建和微針工具的公司現在正在將貿易政策納入其資本計劃。最終，關稅環境凸顯了在將新的非鴉片類藥物貼片技術推向市場時，供應鏈敏捷性、強大的供應商資格認證計劃以及基於場景的成本模型的重要性。

將黏合劑化學、遞送形式、臨床指徵、最終用戶通路和藥物有效載荷選擇與開發和商業化路徑聯繫起來的細緻入微、細分主導的觀點

細分洞察揭示了產品開發、監管策略和上市計劃如何與多樣化的患者需求和醫療保健環境相協調。在考慮黏合劑技術時，丙烯酸、水凝膠和矽膠黏合劑在皮膚耐受性、藥物相容性和佩戴時間性能方面的區別至關重要，每種黏合劑都需要獨特的生物相容性測試和供應鏈考慮。急性病例著重於術後疼痛和運動傷害，優先考慮快速給藥和易於清除；而關節炎和神經病變疼痛等慢性治療則強調持續給藥、長期耐受性和患者依從性。

依產品類型（基質貼片、微針貼片和儲藥貼片）進行區分意味著不同的開發重點。微針選項分為溶解式和固態微針方法，這會帶來與生物分解和設備分類相關的監管和製造限制。同時，具有凝膠或液體儲藥器結構的儲藥貼片變體需要嚴格控制藥物穩定性和釋放動力學。醫院進一步分為私人醫院和公立醫院，診所、居家照護和醫院的最終用戶細分為培訓、庫存管理和報銷途徑。最後，醫院藥局、線上藥局和零售藥局（零售藥局細分為 OTC 和處方箋通路）之間的分銷動態會影響標籤、包裝和病患教育策略。考慮辣椒素、Lidocaine和非類固醇消炎劑化合物的藥物有效載荷，進一步完善臨床定位。

詳細的區域評估，解釋重點地區的法律規範、付款人動態和臨床基礎設施如何影響採用和商業化策略

區域動態決定了非鴉片類貼片市場的投資重點、監管格局和策略夥伴關係。在美洲，完善的臨床基礎設施和新型疼痛管理模式的高採用率，為醫院和診所的採用提供了肥沃的土壤，但報銷談判和採購流程需要提供量身定做的證據包，以證明其相對有效性和實際效用。該地區的供應鏈注重可追溯性和法規遵循性，製造商通常將生產和最終組裝設在靠近終端市場的地方，以控制前置作業時間和關稅。

歐洲、中東和非洲呈現出異質的法規環境，每個國家都有獨特的臨床要求和報銷框架，需要靈活的監管策略和區域付款人的參與。與醫院網路的合作試點計畫可以加速卓越中心的採用，而與區域經銷商的夥伴關係可以幫助應對複雜的進口和採購法規。亞太地區既包括擁有成熟臨床生態系統的已開發市場，也包括醫療保健預算有限的新興市場。在該地區的高所得經濟體中，創新的採用由臨床領導者和私人付款人推動，而在新興市場，製造商必須最佳化成本、供應鏈物流和簡化培訓才能實現有意義的採用。在所有地區，監管清晰度、臨床醫生教育和已證實的患者結果對於擴大非鴉片類藥物貼片的使用仍然至關重要。

競爭格局的策略概況揭示了智慧財產權、夥伴關係、製造能力和證據生成將如何決定非經皮治療領域的領導地位

非鴉片類止痛貼片領域的競爭格局特點是，成熟的製藥和設備公司正在拓展經皮解決方案，而專業的新興企業則專注於微針平台和黏合劑創新。領先的公司正在優先考慮整合策略，將專有的給藥技術與強大的臨床證據包和可擴展的生產能力相結合。與微針幾何形狀、儲庫密封方法和黏合劑化學相關的智慧財產權組合對於保持差異化並在許可和夥伴關係談判中佔據有利地位至關重要。

醫療設備製造商、合約開發與受託製造廠商以及臨床研究網路之間的策略聯盟正變得越來越普遍，以加快臨床開發速度並管理資本密集度。同時，掌握關鍵零件（例如專用醫用聚合物或微加工工具）的公司可以在與供應商的談判中獲得優勢，並影響行業標準。新參與企業往往專注於利基臨床適應症或獨特的交付模式，以建立Proofpoint。在這兩個領域，成功的關鍵在於協調監管策略、擴大生產規模和上市後監測，以建立臨床醫生的信任並支持長期應用。

製造商和相關人員可採取的策略要務是加速採用、加強供應鏈，並將臨床證據與付款人參與和商業執行結合起來

產業領導者應制定綜合藍圖，在科學差異化與實際可行的上市時間之間取得平衡。例如，針對長期慢性適應症，選擇水凝膠和矽膠黏合劑，針對短期急性適應症，選擇丙烯酸黏合劑。投資能夠產生比較有效性和患者報告結果數據的臨床項目，並與大型外科中心和運動醫學診所進行早期合作，以產生令人信服的真實世界證據。

從營運角度來看，我們將實現關鍵投入品供應鏈多元化，並提升二級供應商的資質，以降低關稅和地緣政治風險。我們將考慮近岸製造和區域合作，以縮短前置作業時間並簡化監管申報流程。我們將建造靈活的生產線，能夠容納基質、儲存庫和微針製劑，從而涵蓋多種治療領域。我們將利用健康經濟模型和依從性數據，儘早與付款人互動，以支援覆蓋決策，並設計能夠反映預期分銷管道（例如醫院藥房、線上藥房或需要非處方藥和處方箋標籤的零售管道）的包裝和標籤策略。最後，我們將建立上市後監測通訊協定和數位依從性工具，以捕捉能夠強化臨床醫師和付款人價值提案的成果。

一種透明且嚴格的混合方法研究途徑，將主要臨床和供應鏈訪談與監管、專利和產品文件的技術審查相結合

本執行摘要所依據的初步研究採用了混合方法，強調臨床輸入和嚴格的技術審查。初步研究包括對疼痛專家、採購主管、法規事務專業人員和製造專家的結構化訪談，以了解實際限制、應用促進因素和採購行為。這些見解與同行評審的臨床文獻、公開的監管備案文件、產品標籤和專利披露進行了交叉引用，以確保關於粘合劑化學、微針技術和儲液器構造的技術聲明基於檢驗的公共來源。

營運分析涵蓋了供應商圖譜、組件認證途徑以及透過與製造外包和品質負責人訪談而得出的生產規模考量。透過分析關稅表、與聚合物和設備組件相關的關稅分類，以及對已調整籌資策略的公司案例研究，評估了貿易政策的影響。在整個研究過程中，我們運用了品管措施，包括受訪者檢驗、資訊來源三角測量和調查方法透明度，以最大限度地減少偏差並提高結論的可靠性。由此得出的見解旨在為策略規劃、臨床專案設計和商業性執行提供資訊，而無需依賴專有的市場規模假設。

將非經皮技術能力、臨床證據需求和營運準備與實際採用途徑聯繫起來的明確結論

摘要，非鴉片類止痛貼片代表極具吸引力的治療和商業機遇，需要兼顧技術創新、臨床效用和營運彈性。微針技術、多樣化黏合劑化學和儲存庫結構的進步正在擴大能夠有效治療急性和慢性疼痛的經皮貼片的範圍。成功的市場准入取決於建立可靠的臨床證據，打造靈活且具有韌性的供應鏈以適應貿易政策和投入成本的波動，並以清晰的價值提案贏得付款人和醫療保健系統的青睞。

展望未來，相關人員產品設計與特定臨床路徑結合、投資可擴展的生產和品質系統、並在分銷管道中建立策略夥伴關係關係的利益相關者，將最有能力將創新轉化為持續的臨床應用。鴉片類藥物減量疼痛管理的集體行動提供了令人鼓舞的臨床背景，但要將其潛力轉化為日常實踐，需要在監管、商業和營運領域嚴格執行。本報告中的見解旨在透過實用的實證建議來指導這些決策。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 微針陣列的整合增強了非鴉片類鎮痛藥的經皮輸送
  • 開發生物黏附聚合物基質以延長非鴉片類貼片的配戴時間
  • 奈米載體製劑的出現提高了鎮痛藥的穩定性和皮膚滲透性
  • 在止痛貼片中採用智慧感測器回饋，實現個人化劑量和監測
  • 監管獎勵將加快 FDA 對 CBD 和植物止痛貼的核准流程
  • 製藥和醫療科技公司結成策略聯盟，創新穿戴式止痛貼片平台
  • 轉向可生物分解、環保的貼片背襯，減少一次性塑膠廢棄物

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 非鴉片類止痛貼市場（按技術）

  • 丙烯酸黏合劑
  • 水凝膠黏合劑
  • 矽膠黏合劑

9. 非鴉片類止痛貼市場（依應用）

  • 急性疼痛
    • 術後疼痛
    • 運動傷害引起的疼痛
  • 慢性疼痛
    • 關節炎
    • 神經病變疼痛

10. 非鴉片類止痛貼市場（依產品類型）

  • 矩陣補丁
  • 微針貼片
    • 可溶解微針
    • 實心微針
  • 水庫斑塊
    • 凝膠儲液器
    • 儲液罐

第 11 章非鴉片類止痛貼市場（依最終用戶分類）

  • 診所
  • 居家護理
  • 醫院
    • 私立醫院
    • 公立醫院

12. 非鴉片類止痛貼市場（依通路）

  • 醫院藥房
  • 網路藥局
  • 零售藥局
    • 在商店
    • 處方箋

13. 非鴉片類止痛貼市場（依藥物類型）

  • 辣椒素
  • Lidocaine
  • 非類固醇消炎劑

14. 非鴉片類止痛貼市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第 15 章非鴉片類止痛貼市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

16. 非鴉片類止痛貼市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Hisamitsu Pharmaceutical Co., Inc.
    • Endo International plc
    • Johnson & Johnson
    • Viatris Inc.
    • Perrigo Company plc
    • Haw Par Corporation Limited
    • Upsher-Smith Laboratories, Inc.
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.
    • Sun Pharmaceutical Industries Ltd.
Product Code: MRR-AD36CD897D7B

The Non-opioid Pain Patches Market is projected to grow by USD 2,140.46 million at a CAGR of 13.25% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 790.97 million
Estimated Year [2025] USD 897.06 million
Forecast Year [2032] USD 2,140.46 million
CAGR (%) 13.25%

An executive introduction that clarifies clinical needs, technological advancements, and strategic imperatives shaping the non-opioid transdermal pain patch ecosystem

The non-opioid pain patch landscape is maturing at the intersection of pharmaceutical innovation, advanced materials science, and evolving clinical practice. Novel transdermal systems are gaining traction as clinicians and patients seek localized, opioid-sparing alternatives that address both acute and chronic pain pathways. Concurrent advances in adhesive chemistries, microfabrication, and minimally invasive delivery mechanisms are enabling improved drug bioavailability and more consistent therapeutic profiles compared with older topical formats.

Clinicians are increasingly prioritizing products that demonstrate predictable pharmacokinetics, lower systemic exposure, and compatibility with existing care pathways. Meanwhile, manufacturers are aligning product development with patient-centered design considerations such as wearability, skin tolerability, and ease of administration outside clinical settings. As a result, strategic decisions now hinge on integrating clinical evidence, regulatory clarity, and supply chain resilience. The remainder of this executive summary synthesizes these forces, highlighting the pivotal technology shifts, regulatory and trade headwinds, segmentation-driven opportunities, and pragmatic recommendations that industry leaders can deploy to translate technical promise into commercial and clinical impact.

A detailed synthesis of the converging technology, clinical, and delivery innovations that are reshaping non-opioid transdermal analgesic strategies and provider adoption

The landscape for non-opioid pain patches is undergoing transformative shifts driven by converging advances in delivery technologies, adhesive science, and evidence-based clinical adoption. Microneedle arrays, including dissolvable and solid variants, are moving beyond academic prototypes toward scalable manufacturing, enabling transdermal access to molecules previously restricted by skin permeability. At the same time, adhesive platforms such as acrylic, hydrogel, and silicone formulations are evolving to balance drug compatibility with patient comfort, thereby improving adherence in both acute and chronic care settings.

Concurrently, product design is differentiating across matrix, microneedle, and reservoir configurations with attention to reservoir formulations in both gel and liquid forms. These form factors allow more precise dosing control and prolonged release profiles, which in turn reduce the need for systemic analgesics. Clinical pathways are adapting as hospitals, clinics, and home-care providers integrate patches into multimodal pain protocols, emphasizing postoperative and sports-related acute pain as well as chronic indications such as arthritis and neuropathic pain. In addition, digital enablement-ranging from adherence sensors to integration with electronic health records-amplifies the potential to monitor outcomes and support reimbursement conversations. Taken together, these shifts create a more differentiated competitive landscape where clinical validation and manufacturing scale are decisive.

An evidence-based analysis of how 2025 United States tariff measures are affecting supply chain resilience, procurement strategies, and manufacturing decisions for transdermal therapies

United States tariff policy enacted in 2025 has introduced measurable friction across medical device supply chains, raw-material sourcing, and component imports that underpin transdermal patch manufacturing. Tariff adjustments affecting polymers, adhesive precursors, electronic sensor modules, and specialized microneedle production equipment have prompted manufacturers to reassess supplier relationships and production footprints. In response, some firms are prioritizing nearshoring of critical inputs, qualifying alternative material sources, and accelerating vertical integration to buffer cost variability and lead-time risk.

Beyond direct input cost implications, tariffs have influenced commercial decisions such as inventory strategies and contract terms with original equipment manufacturers. Procurement teams are increasingly negotiating long-term supplier agreements to stabilize unit costs and protect production schedules. Regulatory filings and quality control processes have also been affected, as manufacturers revalidate components when suppliers change. Moreover, tariffs have had an indirect effect on innovation timelines by altering capital allocation; companies weighing investments in automation, cleanroom expansion, or microneedle tooling now factor trade policy into capital planning. Ultimately, the tariff environment underscores the importance of supply chain agility, robust supplier qualification programs, and scenario-based cost modeling when bringing new non-opioid patch technologies to market.

A nuanced segmentation-driven perspective that links adhesive chemistry, delivery formats, clinical indications, end-user channels, and drug payload choices to development and commercialization pathways

Segmentation insights reveal how product development, regulatory strategy, and go-to-market planning must align with diverse patient needs and care settings. When considering adhesive technology, distinctions among Acrylic Adhesive, Hydrogel Adhesive, and Silicone Adhesive matter for skin tolerability, drug compatibility, and wear-time performance, each demanding unique biocompatibility testing and supply chain considerations. Application segmentation separates acute and chronic pain pathways; acute use cases emphasize postoperative pain and sports injury pain where rapid onset and ease of removal are priorities, whereas chronic care targets such as arthritis and neuropathic pain focus on sustained delivery, long-term tolerability, and patient adherence.

Product type differentiation between Matrix Patch, Microneedle Patch, and Reservoir Patch drives divergent development priorities. Microneedle options-differentiated into Dissolvable Microneedle and Solid Microneedle approaches-introduce distinct regulatory and manufacturing constraints related to biodegradation and device classification, while Reservoir Patch variants with Gel Reservoir or Liquid Reservoir architectures require rigorous control of drug stability and release kinetics. End-user segmentation across Clinics, Home Care, and Hospitals, with Hospitals further categorized into Private Hospitals and Public Hospitals, informs training, inventory management, and reimbursement pathways. Finally, distribution dynamics across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy, with Retail Pharmacy subdivided into Over-The-Counter and Prescription channels, influence labeling, packaging, and patient education strategies. Drug payload considerations among Capsaicin, Lidocaine, and Nonsteroidal Anti-Inflammatory Drug compounds further refine clinical positioning, as each molecule has distinct safety, contraindication, and monitoring profiles that shape labeling and commercialization tactics.

An in-depth regional assessment explaining how differing regulatory frameworks, payer dynamics, and clinical infrastructures in key geographies influence adoption and commercialization strategies

Regional dynamics are shaping investment priorities, regulatory pathways, and strategic partnerships across the non-opioid patch landscape. In the Americas, established clinical infrastructure and high adoption rates of novel analgesic modalities create fertile ground for hospital and clinic uptake, yet reimbursement negotiations and procurement processes require tailored evidence packages that demonstrate comparative effectiveness and real-world utility. Supply chain considerations in this region emphasize traceability and regulatory compliance, with manufacturers often locating production or final assembly closer to end markets to manage lead times and tariff exposure.

Europe, Middle East & Africa presents a heterogeneous regulatory environment where country-specific clinical requirements and reimbursement frameworks necessitate flexible regulatory strategies and localized payer engagement. Collaborative pilot programs with hospital networks can accelerate adoption in centers of excellence, while partnerships with regional distributors help navigate complex import and procurement rules. Asia-Pacific encompasses both advanced markets with sophisticated clinical ecosystems and emerging markets with constrained healthcare budgets. In high-income economies within the region, innovation adoption is driven by clinical leadership and private payers, whereas in emerging markets, manufacturers must optimize cost, supply chain logistics, and simplified training to achieve meaningful penetration. Across all regions, regulatory clarity, clinician education, and demonstrable patient outcomes remain vital to scaling non-opioid patch use.

A strategic profile of the competitive landscape highlighting how IP, partnerships, manufacturing capacity, and evidence generation determine leadership in the non-opioid transdermal sector

Competitive dynamics within the non-opioid pain patch sector are characterized by a mix of established pharmaceutical and device firms expanding into transdermal solutions, alongside specialized startups focusing on microneedle platforms and adhesive innovation. Leading organizations are prioritizing integrated strategies that combine proprietary delivery technologies with robust clinical evidence packages and scalable manufacturing capabilities. Intellectual property portfolios around microneedle geometries, reservoir sealing methods, and adhesive chemistries are central to maintaining differentiation and command licensing or partnership negotiations.

Strategic collaborations between device manufacturers, contract development and manufacturing organizations, and clinical research networks are increasingly common as they accelerate time to clinic while managing capital intensity. In parallel, companies that control key components-such as specialized medical-grade polymers and microfabrication tooling-gain leverage in supplier negotiations and can influence industry standards. New entrants tend to focus on niche clinical indications or unique delivery modalities to establish proof points, whereas incumbent players deploy broader commercialization networks and payer engagement expertise. Across the spectrum, success hinges on harmonizing regulatory strategy, manufacturing scale-up, and post-market surveillance to build clinician confidence and support long-term adoption.

Actionable strategic imperatives for manufacturers and stakeholders to accelerate adoption, strengthen supply chains, and align clinical evidence with payer engagement and commercialization execution

Industry leaders should pursue an integrated roadmap that balances scientific differentiation with pragmatic go-to-market execution. Prioritize development of adhesive and delivery platforms that match the intended clinical use; for example, select hydrogel or silicone adhesives for long-wear chronic indications while favoring acrylic systems for short-duration acute applications. Invest in clinical programs that generate comparative effectiveness and patient-reported outcome data, with early collaborations in high-volume surgical centers and sports medicine clinics to create compelling real-world evidence.

From an operational perspective, diversify supply chains for critical inputs and qualify secondary suppliers to mitigate tariff and geopolitical risks. Explore nearshore manufacturing or regional partnerships to reduce lead times and simplify regulatory filings. Build flexible production lines that can accommodate matrix, reservoir, and microneedle formats to capture multiple therapeutic niches. Engage payers early with health economic models and adherence data to support coverage decisions, and design packaging and labeling strategies that reflect the intended distribution channel-whether hospital pharmacy, online pharmacy, or retail channels requiring OTC or prescription classification. Finally, establish post-market surveillance protocols and digital adherence tools to collect outcomes that reinforce value propositions for clinicians and payers alike.

A transparent and rigorous mixed-methods research approach combining primary clinical and supply chain interviews with technical review of regulatory, patent, and product documentation

The research synthesis underpinning this executive summary used a mixed-methods approach that emphasizes primary clinical input and rigorous technical review. Primary research included structured interviews with pain specialists, procurement leaders, regulatory affairs professionals, and manufacturing experts to capture practical constraints, adoption drivers, and procurement behaviors. These insights were triangulated with a targeted review of peer-reviewed clinical literature, public regulatory filings, product labeling, and patent disclosures to ensure technical assertions about adhesive chemistries, microneedle technologies, and reservoir architectures are grounded in verifiable public materials.

Operational analyses incorporated supplier mapping, component qualification pathways, and manufacturing scale considerations derived from interviews with contract manufacturing organizations and quality leaders. Trade policy impacts were evaluated through analysis of tariff schedules, customs classifications relevant to polymer and device components, and case studies of firms that adjusted sourcing strategies. Throughout the research process, quality control measures such as respondent verification, source triangulation, and methodological transparency were applied to minimize bias and enhance the reliability of conclusions. The resulting insights are intended to inform strategic planning, clinical program design, and commercial execution without relying on proprietary market-sizing assumptions.

A decisive conclusion that ties technological capabilities, clinical evidence needs, and operational readiness to practical adoption pathways for non-opioid transdermal therapies

In summary, non-opioid pain patches represent a compelling therapeutic and commercial opportunity contingent on harmonizing technological innovation with clinical utility and operational resilience. Advances in microneedle technologies, diverse adhesive chemistries, and reservoir architectures are expanding the range of transdermal solutions that can effectively treat both acute and chronic pain indications. Successful market entry depends on generating robust clinical evidence, building flexible and resilient supply chains that can respond to trade-policy and input-cost volatility, and engaging payers and health systems with clear value propositions.

Going forward, stakeholders that align product design with specific clinical pathways, invest in scalable manufacturing and quality systems, and nurture strategic partnerships across distribution channels will be best positioned to translate technical innovation into sustained clinical adoption. The collective movement toward opioid-sparing pain management provides an encouraging clinical backdrop, but converting that potential into routine practice requires disciplined execution across regulatory, commercial, and operational domains. This report's insights aim to guide those decisions with practical, evidence-informed recommendations.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of microneedle arrays to enhance transdermal delivery of non-opioid analgesics
  • 5.2. Development of bioadhesive polymer matrices to extend non-opioid patch wear duration
  • 5.3. Emergence of nanocarrier formulations improving stability and skin permeation of analgesics
  • 5.4. Adoption of smart sensor feedback in pain patches for personalized dosing and monitoring
  • 5.5. Regulatory incentives accelerating FDA approval pathways for CBD and botanical pain patches
  • 5.6. Strategic collaborations between pharma and medtech firms to innovate wearable pain patch platforms
  • 5.7. Shift towards biodegradable and eco-friendly patch backings to reduce single-use plastic waste

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Non-opioid Pain Patches Market, by Technology

  • 8.1. Acrylic Adhesive
  • 8.2. Hydrogel Adhesive
  • 8.3. Silicone Adhesive

9. Non-opioid Pain Patches Market, by Application

  • 9.1. Acute Pain
    • 9.1.1. Postoperative Pain
    • 9.1.2. Sports Injury Pain
  • 9.2. Chronic Pain
    • 9.2.1. Arthritis
    • 9.2.2. Neuropathic Pain

10. Non-opioid Pain Patches Market, by Product Type

  • 10.1. Matrix Patch
  • 10.2. Microneedle Patch
    • 10.2.1. Dissolvable Microneedle
    • 10.2.2. Solid Microneedle
  • 10.3. Reservoir Patch
    • 10.3.1. Gel Reservoir
    • 10.3.2. Liquid Reservoir

11. Non-opioid Pain Patches Market, by End User

  • 11.1. Clinics
  • 11.2. Home Care
  • 11.3. Hospitals
    • 11.3.1. Private Hospitals
    • 11.3.2. Public Hospitals

12. Non-opioid Pain Patches Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy
    • 12.3.1. Over-The-Counter
    • 12.3.2. Prescription

13. Non-opioid Pain Patches Market, by Drug Type

  • 13.1. Capsaicin
  • 13.2. Lidocaine
  • 13.3. Nonsteroidal Anti-Inflammatory Drug

14. Non-opioid Pain Patches Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Non-opioid Pain Patches Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Non-opioid Pain Patches Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Hisamitsu Pharmaceutical Co., Inc.
    • 17.3.2. Endo International plc
    • 17.3.3. Johnson & Johnson
    • 17.3.4. Viatris Inc.
    • 17.3.5. Perrigo Company plc
    • 17.3.6. Haw Par Corporation Limited
    • 17.3.7. Upsher-Smith Laboratories, Inc.
    • 17.3.8. Novartis AG
    • 17.3.9. Teva Pharmaceutical Industries Ltd.
    • 17.3.10. Sun Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. NON-OPIOID PAIN PATCHES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. NON-OPIOID PAIN PATCHES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NON-OPIOID PAIN PATCHES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACRYLIC ADHESIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACRYLIC ADHESIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACRYLIC ADHESIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACRYLIC ADHESIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACRYLIC ADHESIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACRYLIC ADHESIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HYDROGEL ADHESIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HYDROGEL ADHESIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HYDROGEL ADHESIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HYDROGEL ADHESIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HYDROGEL ADHESIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HYDROGEL ADHESIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY SILICONE ADHESIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY SILICONE ADHESIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY SILICONE ADHESIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY SILICONE ADHESIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY SILICONE ADHESIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY SILICONE ADHESIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY POSTOPERATIVE PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY POSTOPERATIVE PAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY POSTOPERATIVE PAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY POSTOPERATIVE PAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY POSTOPERATIVE PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY POSTOPERATIVE PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY SPORTS INJURY PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY SPORTS INJURY PAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY SPORTS INJURY PAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY SPORTS INJURY PAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY SPORTS INJURY PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY SPORTS INJURY PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ARTHRITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ARTHRITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ARTHRITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ARTHRITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ARTHRITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY NEUROPATHIC PAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY NEUROPATHIC PAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY NEUROPATHIC PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY NEUROPATHIC PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY MATRIX PATCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY MATRIX PATCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY MATRIX PATCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY MATRIX PATCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY MATRIX PATCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY MATRIX PATCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISSOLVABLE MICRONEEDLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISSOLVABLE MICRONEEDLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISSOLVABLE MICRONEEDLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISSOLVABLE MICRONEEDLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISSOLVABLE MICRONEEDLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISSOLVABLE MICRONEEDLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY SOLID MICRONEEDLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY SOLID MICRONEEDLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY SOLID MICRONEEDLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY SOLID MICRONEEDLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY SOLID MICRONEEDLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY SOLID MICRONEEDLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY GEL RESERVOIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY GEL RESERVOIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY GEL RESERVOIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY GEL RESERVOIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY GEL RESERVOIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY GEL RESERVOIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY LIQUID RESERVOIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY LIQUID RESERVOIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY LIQUID RESERVOIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY LIQUID RESERVOIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY LIQUID RESERVOIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY LIQUID RESERVOIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY OVER-THE-COUNTER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY OVER-THE-COUNTER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY OVER-THE-COUNTER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY OVER-THE-COUNTER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY OVER-THE-COUNTER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY OVER-THE-COUNTER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRESCRIPTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRESCRIPTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRESCRIPTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRESCRIPTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRESCRIPTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CAPSAICIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CAPSAICIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CAPSAICIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CAPSAICIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CAPSAICIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY CAPSAICIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY LIDOCAINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY LIDOCAINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY LIDOCAINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY LIDOCAINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY LIDOCAINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY LIDOCAINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL NON-OPIOID PAIN PATCHES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, 2025-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, 2025-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, 2018-2024 (USD MILLION)
  • TABLE 272. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, 2025-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 280. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. LATIN AMERICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY ACUTE PAIN, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY CHRONIC PAIN, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY MICRONEEDLE PATCH, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY RESERVOIR PATCH, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID PAIN PATCHES MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)

TABLE